XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial

ConclusionsA clearer understanding of the endothelialization process of new generation DES could significantly impact the treatment with dual antiplatelet therapy in the future. Moreover, although not powered for clinical end-points, the XLIMIT trial will provide randomized data in a population with minimal exclusion criteria.Trial registrationClinicalTrials.gov Identifier: NCT03745053. Registered on November 19, 2018.
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research
More News: Cardiology | Heart